NEW YORK (GenomeWeb) – Having consolidated its test development efforts to focus on the urologic oncology market, Belgium's MDx Health is planning to launch at least one new test for bladder cancer this year after releasing its second prostate cancer test, SelectMDx, this spring.

SelectMDx is urine-based methylation assay that can help stratify patients who have clinical factors that suggest they need a prostate biopsy, such as high PSA levels, into those at higher and lower risk, helping to avoid unnecessary procedures.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.